Revance Therapeutics Newsroom

Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.

Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.

Dow JonesMay 13 12:47 ET

Revance Therapeutics Is Maintained at Neutral by Goldman Sachs

Revance Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow JonesMay 13 12:03 ET

Express News | Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8

BenzingaMay 13 11:52 ET

Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)

TipRanksMay 13 03:46 ET

Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...

Yahoo FinanceMay 10 15:04 ET

Revance Therapeutics Down Over 21%, on Pace for Largest Percent Decrease Since October 2021 -- Data Talk

Revance Therapeutics, Inc. (RVNC) is currently at $3.37, down $0.92 or 21.42% --Would be lowest close since April 25, 2024, when it closed at $3.29 --On pace for largest percent decrease since Oct.

Dow JonesMay 10 14:35 ET

NVAX, GRPN and MVIS Among Mid-day Movers

Seeking AlphaMay 10 12:57 ET

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents

BenzingaMay 10 12:44 ET

12 Health Care Stocks Moving In Friday's Intraday Session

GainersNovavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out to

BenzingaMay 10 12:31 ET

Express News | Revance Therapeutics Shares Are Trading Lower Following Mixed Q1 Earnings

BenzingaMay 10 11:11 ET

Earnings Call Summary | Revance Therapeutics(RVNC.US) Q1 2024 Earnings Conference

The following is a summary of the Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript:Financial Performance:Q1 2024 revenue of $51.9 million reported, a 13% increase due to DAXXIFY.Net r

moomoo AIMay 10 10:53 ET · Conference Call

Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating

Revance Therapeutics (RVNC) has an average outperform rating and price target range of $6 to $32, according to analysts polled by Capital IQ. Price: 3.26, Change: -1.04, Percent Change: -24.13

MT NewswiresMay 10 10:20 ET

Novavax, Macrogenics, Biofrontera Among Healthcare Movers

Seeking AlphaMay 10 10:00 ET

These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results

Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday.Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63

BenzingaMay 10 09:23 ET

Express News | Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8

BenzingaMay 10 08:05 ET

Piper Sandler Sticks to Its Buy Rating for Revance Therapeutics (RVNC)

TipRanksMay 10 08:04 ET

Revance Therapeutics Is Maintained at Buy by Needham

Revance Therapeutics Is Maintained at Buy by Needham

Dow JonesMay 10 07:08 ET

Revance Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 172.73% Needham $18 → $12 Maintains Buy 03/01/2024 104.55% Goldman Sachs $8 → $9 Maintains Neut

BenzingaMay 10 06:56 ET

Express News | Revance Therapeutics Inc : H.c. Wainwright Cuts Target Price to $11

ReutersMay 10 06:51 ET

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)

TipRanksMay 10 06:50 ET